Pharmaceutical Technology

MAY 24, 2023

The ability to modify or introduce genetic material in human cells in such a precise and patient-centered manner clearly constitutes a breakthrough in personalized medicine. What are the general differences in the supply chain of CGT vs. traditional clinical trials? Differences in CGT vs traditional trials supply chain.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Camargo

NOVEMBER 11, 2020

In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, the U.S.

Development 242

Development Bioequivalency Generic Drugs Production 242

Drug Discovery World

NOVEMBER 15, 2022

Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

AUGUST 17, 2020

To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics.

Protein 98

Protein Engineer Immune Response In-Vivo 98